Wisconsin State Laboratory of Hygiene Board of Directors Meeting September 15, 2020 Madison, Wisconsin

DATE: September 9, 2020

 TO: Dean Robert N. Golden, MD, UW-SMPH – Dr. Richard Moss, Designated Representative Andrea Palm, Secretary, DHS – Charles Warzecha, Deputy Designated Representative Stephanie Smiley, Administrator, DPH – Charles Warzecha, Deputy Designated Representative Preston Cole, Secretary, DNR – Greg Pils, Designated Representative Brad Pfaff Secretary, DATCP –Gilbert (Gil) Kelley, Designated Representative Charles Warzecha, Chair James Morrison, Vice-Chair Barry Irmen, Member Jeffery Kindrai, Member Dr. Richard Moss, Member Dr. Robert Corliss, Member Zana Sijan, DNR Alternate Steve Geis, DNR Alternate

- FROM:Dr. James Schauer, Secretary
Director, Wisconsin State Laboratory of Hygiene
- RE: Wisconsin State Laboratory of Hygiene Board of Directors Meeting Wisconsin State Laboratory of Hygiene ***Online Meeting***

September 15, 2020 1:00 p.m. — 3:00 p.m.

C:

Dr. Allen Bateman Allen Benson Cynda DeMontigny Kristine Hansbery Dr. Kayley Janssen Kevin Karbowski Jan Klawitter Dr. Daniel Kurtycz Erin Mani Dr. Errin Rider Dr. Peter Shult Dr. Kaitlin Sundling Ernie Stracener Steve Strebel David Webb

WISCONSIN STATE LABORATORY OF HYGIENE BOARD OF DIRECTORS

MEETING NOTICE

Tuesday, September 15, 2020

1:00p.m. – 3:00p.m.

MEETING LOCATION: Conference Line: 1(877) 336-1828 Access Code: 4271573

Notice is hereby given that the Wisconsin State Laboratory of Hygiene Board of Directors will convene at <u>1:00 p.m. on Tuesday, September 15, 2020</u> via teleconference, followed by a closed session at the meeting conclusion per "section 19.85(1)(c), Wis. Stats., to consider employment, promotion, compensation or performance evaluation data of public employees over which the governmental body has jurisdiction or exercises responsibility."

Notice is further given that matters concerning Wisconsin State Laboratory of Hygiene issues, program responsibilities or operations specified in the Wisconsin Statutes, which arise after publication of this notice may be added to the agenda and publicly noticed no less than two hours before the scheduled board meeting if the board Chair determines that the matter is urgent.

Notice is further given that this meeting may be conducted partly or entirely by teleconference or videoconference.

Notice is further given that questions related to this notice, requests for special accommodations, or requests for a public appearance are addressed by the Wisconsin State Laboratory of Hygiene Administrative Offices by phone at (608) 890-0288 or in writing to the Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, Wisconsin, 53706.

ORDER OF BUSINESS: See agenda.

Respectfully submitted,

Lat Soli

James J. Schauer, PhD, P.E., M.B.A. Secretary, Wisconsin State Laboratory of Hygiene Board of Directors Director, Wisconsin State Laboratory of Hygiene

Wisconsin State Laboratory of Hygiene Board of Directors Meeting September 15, 2020 1:00 P.M. – 4:00 P.M.

Wisconsin State Laboratory of Hygiene ***ONLINE MEETING***

AGENDA

PROCED	URAL ITEMS	PAGE
Item 1.	ROLL CALL	4
ltem 2.	APPROVAL OF MINUTES	5
Item 3.	REORGANIZATION OF AGENDA	13
ltem 4.	PUBLIC APPEARANCES	14
ltem 5.	BOARD MEMBERS' MATTERS	16
BUSINES	<u>S ITEMS</u>	
	NTRODUCTION TO DR. ERRIN RIDER & ROLE AS ASSOCIATE	17
	ganizational Chart Update	
Item 7.	COVID-19 TESTING & RESPONSE	18
Item 8.	IMPACT OF COVID-19 PANDEMIC ON CYTOLOGY TESTING IN WISCONSIN	19
Item 9.	WisCON & COVID-19 RESPONSE	20
Item 10.	PFAS & COVID-19 ENVIRONMENTAL TESTING	21
Item 11. • Co	FINANCIAL REPORT ontracts Report	22
Item 12.	HR UPDATE	30
Item 13.	DIRECTOR'S REPORT	31
• Pu	Iblic Relations Report	

Water Boil Notice Report

PROCEDURAL ITEMS

Item 1. ROLL CALL

Description of Item:

Roll call of attendance at Board Meeting led by Board Chair.

<u>Suggested Board Action:</u> Submit roll call.

Staff Recommendation and Comments:

Roll call will be recorded by Board Secretary.

PROCEDURAL ITEMS

Item 2. APPROVAL OF MINUTES

Description of Item:

The draft minutes of the June 16th, 2020 board meeting are submitted for approval.

Suggested Board Action:

Motion: Approve the draft minutes of the June 16th, 2020 board meeting as submitted.

Staff Recommendation and Comments:

Approve draft minutes.

Once approved, minutes become part of the public record and are posted on the WSLH website: <u>http://www.slh.wisc.edu/about/board/board-meetings-agendas-and-minutes/</u>.

APPROVED MINUTES June 16, 2020 1:00 P.M. – 4:00 P.M. Wisconsin State Laboratory of Hygiene 2601 Agriculture Drive Madison, WI 53718

MEMBERS PRESENT:	Chair Dr. Robert Corliss, Vice-Chair Charles Warzecha Secretary Dr. James Schauer, Jeffery Kindrai, James Morrison, Dr. Richard Moss, Greg Pils, Steve Geis, Gil Kelley
WSLH STAFF PRESENT:	Dr. Dan Kurtycz, Dr. Pete Shult, Dave Webb, Jan Klawitter, Kristine Hansbery, Allen Benson, David Webb, Cynda DeMontigny, Kevin Karbowski, Steve Strebel, Camille Danielson, and Nathaniel Javid
DNR STAFF PRESENT:	Zana Sijan, Steve Geis
GUESTS PRESENT:	None

Chair Charles Warzecha made a motion to call the meeting to order at 1:05 P.M. Jeffery Kindrai accepted the motion and Dr. Richard Moss seconded the motion. The meeting was called to order at 1:05 P.M.

Item 1. ROLL CALL

Chair Charles Warzecha initiated the roll call of the Board. Nathaniel Javid conducted the roll the call of the Board members. All Board Member seats or their designated representatives were present. There were no attendees on the public telephone line.

Item 2. APPROVAL OF MINUTES

Approve the minutes of the March 24, 2020 Board Meeting as submitted. **Chair Charles Warzecha** entertained a motion to approve the minutes, so moved by **Barry Irmen**. **Dr. Robert Corliss** seconded the motion. The voice vote approving the minutes was unanimous.

Item 3. REORGANIZATION OF AGENDA

There was no request to reorganize the agenda.

Item 4. PUBLIC APPEARANCES

There were no public appearances.

Item 5. BOARD MEMBERS' MATTERS

Charles Warzecha noted that COVID-19 continues to be all consuming. Barry Irmen mentioned that he has appreciated all of the support with testing in this time and the turnaround time has been excellent. Charles Warzecha noted a few retirements within DHS, and these positions interact with the Wisconsin State Laboratory of Hygiene. This will be a significant recruitment, and on an interim basis, Charles Warzecha will fill in these roles.

Item 6. IMPACT OF COVID-19 ON WSLH OPERATIONS

■ David Webb, WSLH Environmental Health Division Director

David Webb summarized the WSLH response to COVID-19 in this time. Mr. Webb noted that in mid-March we have activated our Continuity of Operations Plan (COOP). We managed throughout safer-at-home orders, and we were declared to be essential. We worked with our stakeholders for engagement about essential services. Because of this, we quickly shifted into incident command mode to consolidate and coordinate communications. In order to have an effective teamwork response, we needed to address infrastructure and staffing, workload impacts, state and UW emergency operations, and our campus and DOA partners. As far as infrastructure and staffing, at our three facilities, we had do re-engineer our front desk, work with the DOA on more intensive cleaning, limiting visitors and vendors, imposing restrictions on travel, lowering staff density, and making masks and hand sanitizer readily available. Also, we used significant inter-divisional support to our Communicable Disease Division to enhance capacity. Mr. Webb presented pictures to the Board of some of these modifications such as the front desk areas. Mr. Webb also presented some data on WSLH staffing including staff working at t the lab, versus working remotely, and on leave. COVID-19 has impacted each division's workload different. There has been an increase workload with COVID and PFAS, but a minimal impact in Proficiency Testing, Newborn Screening, Human Resources, Finance and IT. There has been a moderate drop in work for Forensic Toxicology. Clean Water Act work. Cytology. and Cytogenetics. There has been a large drop in OSHA, Beach/recreational testing, and discretionary monitoring.

For the Emergency Operations Center, there has been much UW and state efforts including daily interactions with DHS, frequent communications at various levels with the UW, WisCON support for PPE, DOA building management to assist in preparedness, aid in PPE distribution including masks and hand sanitizer, and helping navigate communication. Lastly, as far as operational changes, we have had numerous communications and guidance to reconcile, visitor access and review of each circumstance, mask and leave usage, and working together.

Jim Morrison thanked David Webb for his presentation and the work the WSLH is doing. Mr. Morrison asked about supply chain and if there had been any interruptions. Dr. Jamie Schauer replied that this will be address in Dr. Alana Sterkel's presentation later in the meeting. Jeffery Kindrai asked about the varying guidance that is available. Dr. Schauer reiterated that since we are part of UW campus, and campus employees, we will be following campus guidance.

Item 7. PFAS RESEARCH UPDATE

■ Dr. Martin Shafer, WSLH Environmental Health Division

Dr. Martin Shafer gave an update on PFAS research initiatives that are ongoing or recently completed. Some of the initial studies have been focused on atmospheric transport, processing and deposition is underappreciated and under-studied. There are different PFAS compounds we need to consider including carboxylic acids, sulfonates, fluorotelomers, and sulfonamides. We decided to determine if the NADP infrastructure would be acceptable for measuring PFAS depositions (composition in the rain and detected in the terrestrial environment) using current sample collection methods. We broadened the number of PFAS compound evaluated (few studies quantify more than 20 compounds). We next needed to initiate a synoptic overview study of PFAS concentrations in precipitation across the US, knowing that the extant data is quite limited. Lastly, we needed to improve the quality assurance documentation of PFAS precipitation studies (there is limited QA in many of the few published studies).

In summary, the outcomes of the efficacy study was that the loss of PFAS is minimal for compounds of carob number <10 under current National Trends Network (NTN) protocols, so the current NTN protocols work for a broad range of PFAS compounds. Alternate handling/collection protocols can be implemented to address losses of longer-chain compounds. Overall, precipitation and air are effective monitoring matrices for detection of trends. Dr. Shafer presented graphs showing the levels of PFAS at 30 sites. Some of the concentrations are significant along with fluctuations. We can then convert these concentrations to depositions. Eventually, we hope to get enough data to develop maps to help us understand where PFAS are sourced from along with regional and global indications of where PFAS is.

We have developed a standardized robust protocol (SOP) for PFAS wet-deposition measurements using the NADP-NTN infrastructure. This incorporates optimized analytical methods, serves as a model for other emerging contaminants, and could support some other state-wide and regional deposition work that we are doing. Dr. Shafer noted that there are major unresolved issues such as the role of point, regional and global emission sources at a given location. One of the exciting studies going on right now, is a WDNR study collecting weekly samples for 14 weeks looking for 36 PFAS compounds at all 7 NADP-NTN sites in Wisconsin. Dr. Shafer also noted another study funded by the WDNR on the assessment of the impacts of PFAS in municipal wastewater effluents and land-spread biosolids on Wisconsin Ground-and Surface waters.

Dr. Shafer noted some PFAS collaborations with NADP and the EPA along with WSLH and WDNR. Dr. Shafer explained the expansion of synoptic sampling using NADP infrastructure over time. Also, the WSLH has initiated development of an expanded comprehensive method for PFAS in human serum. The goal is up to 40 compounds and this effort is in-part supported by a \$50K grant from the Association of Public Health Laboratories. Dr. Shafer reviewed some PFAS methods for drinking water, non-potable water, wastewater, solids, and tissues. Dr. Shafer noted the status of our PFAS accreditation all these methods as we are awaiting WDNR accreditation in these methods.

Dr. Alana Sterkel, Communicable Disease Division, Wisconsin State Laboratory of Hygiene

Dr. Sterkel presented an overview of COVID-19 at the WSLH. February 5th was the first case of COVID in Wisconsin and the WSLH officially started testing on March 2nd. Staff have been cross-trained to meet the exploding demand. We have worked with WDHS to set tier testing criteria to allow us to focus on high risk patients. There were some issues with the supply chain that threatened to shut down testing; however, our strategy for testing diversification allows us to source multiple supply lines and we never went down. Through our Wisconsin Clinical Laboratory Network, we have helped 68 labs in Wisconsin start testing to date, with 25 more in the works. So far, we have tested over 17,000 specimens at the WSLH. In addition, we have had to manage the challenge of continuing other mission critical work.

Dr. Sterkel reviewed some different equipment that have been used and how we have upgraded in this time to increase our capacity. At first, we started at a 50 tests per day capacity and now we are at 500 tests per day capacity. This equipment can be used with other testing methods which further proves it's utility. Although we are currently at 500/day capacity, for the future we plan to have an 800 or more/day capacity. The greatest bottleneck in testing is the pre-analytical stage which includes data entry and specimen processing. As far as serology, we are employing three surveillance strategies. These include a 1000 samples/month partnership with SHOW, a 1000 samples/month partnership with other surveillance sites, and lastly collecting data from other labs. Another testing approach we have taken has been through sequencing. This is detail that allows for genetic comparisons and phylogenetic tree assembly and can be used by epidemiologists for outbreak response.

Dr. Sterkel noted that we have been able to obtain funding totaling \$21, 844, 104 from ELC emergency funds, ELC Cares, and ELC Enhancing Detection. We have also been able to improve efficiencies as we've progressed to help us save costs. Dr. Sterkel explained the outreach done through the Wisconsin Clinical Laboratory Network (WCLN) via their detailed webpage on the WSLH website. This includes information on validation panels, 10 webinars, lab messages, an email listserv for community discussion, and providing technical consultation. Dr. Sterkel presented the collection kits timeline from March until June and a live survey that was employed to monitor testing services throughout the state. Dr. Sterkel presented data on laboratories actively testing, laboratories planning to test, and current state capacity along with state and federal goals.

Dr. Sterkel noted that the WSLH has been asked by campus to support massive testing of students and faculty. We were clear that this could not be absorbed into our existing testing efforts, but we are working with the Wisconsin Veterinary Diagnostic Laboratory to develop a plan to meet the needs of campus. Overall, the WSLH is a valuable resource for Wisconsin's COVID-19 pandemic response through testing, leadership, and technical expertise. Diversification in test strategies has allowed us to continue to meet the needs of our clients through maintaining a 48 hour turnaround time and never stopping testing. The external partnerships we have strengthened Wisconsin's response to the pandemic.

Item 9. WASTEWATER SURVEILLANCE OF SARS-COV-2 IN WISCONSIN

Dr. Martin Shafer, WSLH Environmental Health Division

Dr. Shafer noted that our overarching goal of this project is to determine whether, and to what extent, the SARS-CoV-2 virus is circulating in communities, both large and small, across Wisconsin. While testing individuals for the virus can provide definitive evidence of the virus in the population, it is not always practical. SARS-CoV-2 is shed from humans in their fecal matter. Sanitary sewer systems collect and aggregate wastewater to a central location and by the time it reaches the plant, it is a well-mixed sample of many households and businesses; thus by sampling the influent at the wastewater treatment facility (WWTF) a representative snapshot of the whole community served by WWTF can be obtained. This study is designed to tell us if transmission is increasing or decreasing in a given community. It also tell us if COVID-19 is circulating in the community and can serve as an early warning potential. This approach is not designed to replace existing public health surveillance systems, but to supplement them.

Dr. Shafer provided a synopsis of the study approach so that the data is robust. This will run for a one-year period. The data will be used for public health action, acting as an early warning system, elucidating the correlation between wastewater viral RNA concentrations and population epidemiology of COVID-19. The data will be released by the DHS to the public. Last, Dr. Shafer noted the ways in which we are working to establish best practices including weekly calls and method sharing and participating in various studies.

Item 10. FINANCIAL REPORT

Kevin Karbowski, Chief Financial Officer, Wisconsin State Laboratory of Hygiene

Mr. Karbowski presented the statement of income to the Board for the period of July 1, 2019 through April 30, 2020. Our year to date expected loss was \$150,664. Due to COVID-19, our year to date actual loss is \$1,181,122. This leaves us a significant variance of \$1,030,458. Mr. Karbowski reviewed some of the larger variances on the income statement that are mostly the result of the effects of COVID. Most of these variances are due to COVID. losing money on newborn screening and clinical testing. This is offset by additional COVID work. We are hoping this loss will improve over the next few months. As far as working capital, our available working capital has decreased by \$1,415,614. This is mainly because of the amount we lost on operations and we needed to purchase newborn screening equipment. Although newborn screening is currently not operating in the black, we need to make the purchases in order to maintain accreditation. Dr. Schauer noted that although we show a loss this year, we had a profit the last two years, so this has somewhat evened out. Dr. Schauer also noted that as far as newborn screening, we have to continue funding it as it is an essential program. Overall, our available working capital as of April 30, 2020 is \$7,959,700. Mr. Karbowski presented the contracts summary totaling \$4,363,101 divided amongst the WDNR, Department of Justice, Association of Public Health Laboratories, and WDHS. Mr. Karbowski had the Board refer to the packet for more details.

Item 11. FY21 BUDGET APPROVAL

Kevin Karbowski, Chief Financial Officer, Wisconsin State Laboratory of Hygiene

Mr. Karbowski noted that due to COVID-19, we have had to make some major changes to the planning of our budget. We are assuming a slow shift to normal operations over the next several months. For total support and revenue on an accrual basis, we are budgeting \$51,825,336. For expenses on an accrual basis, we are budgeting total expenses of \$52,031,595. This gives us a net operating loss of \$206,259. This is more or less a break-even budget. Mr. Karbowski noted that we are expecting increases in COVID dollars and an increase in PFAS dollars that will help us in the future. Mr. Karbowski noted some things we are monitoring with newborn screening expenses. Dr. Schauer noted that we do expect additional funding with an additional workload. Mr. Karbowski noted that expenses in the lab are relatively stable, with the exception of salaries in making offers to new employees to attract them to the University.

Mr. Karbowski noted that the WSLH is seeking the approval of the Board for this FY21 budget. Jeffery Kindrai made a motion to approve the budget as presented. Barry Irmen seconded this motion. There was no discussion at the WSLH FY21 Budget was approved.

Item 12. STRATEGIC PLAN UPDATE

Kevin Karbowski, Chief Financial Officer, Wisconsin State Laboratory of Hygiene

Mr. Karbowski noted that we asked WSLH employees to submit proposals for innovation project grants as part of our Strategic Plan. We received twenty proposals, and of those twenty, four have been completed. These completed projects are a data tracking database, development of water analysis method, improved zika test kits, and enhanced recycling at our Agriculture Drive facility. Eleven additional projects are close to being done. Unfortunately, we had one project that could not be completed as we could not find an acceptable piece of equipment to purchase for the project. We have several other projects on hold due to COVID-19 and staff turnover.

Item 13. HUMAN RESOURCES REPORT

Cynda DeMontigny, Human Resources Director, Wisconsin State Laboratory of Hygiene

Ms. DeMontigny provided the HR update for the period of March 11 through June 5, 2020. We had a total of 6 recruitments, with one in our Disease Prevention Division and our Environmental Health Division, two in our Communicable Disease Division and Administration, and none in our Laboratory Improvement Division and Occupational Health Division. As far as staff turn-around, we had four hires in our Environmental Health Division and one in our Disease Prevention Division, one resignation each in our Communicable Disease Division and Administration, three resignations in our Environmental Health Division, and two resignations in our Disease Prevention Division. We had one retirement in Administration.

■ Dr. James Schauer, Director, Wisconsin State Laboratory of Hygiene

Jan Klawitter reviewed some of the WSLH recent events with the Board. These include articles in UW SMPH Quarterly and the Blastomycosis journal. Also, Ms. Klawitter noted some of the items that were touched on in the earlier presentations about PFAS in human serum research along with wastewater surveillance of SARS-CoV-2. Ms. Klawitter also noted the NADP Spring Meeting, which happened virtually this year. Ms. Klawitter had the Board refer to the packet for more details on these and other recent events.

Dr. Schauer noted there were no water boil notices for this period.

Dr. Schauer noted that there was a state soils lab that was operating on campus, but we will be merging with them in the coming months. This will be a soil health lab and will fit in well with what we do. This will be about 1% of the WSLH financial operations and we will give more updates to the Board as we move forward.

We will be following up on filling the vacant WSLH Board seats. Dr. Schauer asked the Board for any input they have. We would make recommendations to the Governor's office, but the ultimate decision would be with the Governor's office.

Charles Warzecha thanked the WSLH for all of the remarkable work and leadership they have provided in this time for the COVID-19 response.

Chair Charles Warzecha made a motion to adjourn the meeting at 3:25 P.M. **Jeffery Kindrai** accepted the motion and **James Morrison** seconded the motion. The motion passed unanimously and the meeting was adjourned.

Respectfully submitted by:

h Ja Soli

James J. Schauer, PhD, P.E., M.B.A. Secretary, Wisconsin State Laboratory of Hygiene Board of Directors

PROCEDURAL ITEMS

Item 3. REORGANIZATION OF AGENDA

Description of the Item:

Board members may suggest changes in the order in which agenda items are discussed.

Suggested Board Action:

None.

Staff Recommendation and Comments:

Reorganize the agenda if requested by the Board.

PROCEDURAL ITEMS

Item 4. PUBLIC APPEARANCES

Description of the Item:

Under the board's Policies and Procedures nonmembers are invited to make presentations.

Suggested Board Action:

Follow WSLH Policies and Procedures.

Staff Recommendation and Comments:

Follow WSLH Policies and Procedures.

Per Policies and Procedures of the Wisconsin State Laboratory of Hygiene Board of Directors:

- §6.12 Speaking privileges. When the board is in session, no persons other than laboratory staff designated by the director shall be permitted to address the board except as hereinafter provided:
 - (a) A committee report may be presented by a committee member who is not a member of the board.
 - (b) A board or committee member in the course of presenting a matter to the board may request staff to assist in such a presentation.
 - (c) If a board member directs a technical question for clarification of a specific issue to a person not authorized in this section, the Chair may permit such a person to respond.
 - (d) The board may by majority vote or by decision of the Chair allow persons not otherwise authorized in this section to address the board if the situation warrants or the following criteria is followed:
 - (1) Written requests for public appearances on specific current agenda items shall be made to the board Secretary <u>no later than two working days</u> prior to the meetings. The request shall outline the reasons for the request including the subject matter to be discussed in as much detail as is feasible prior to the meeting of the board. Those requesting an appearance may, at or prior to the board meeting, provide board members copies of any written materials to be presented or a written statement of a position.
 - (2) Individual presentations will be limited to five minutes, unless otherwise authorized by the Chair.
 - (3) To schedule an appearance before the Wisconsin State Laboratory of Hygiene Board of Directors, contact the board Secretary, c/o Director, Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, Wisconsin 53706. Telephone (608) 890-0288. The subject or subjects to be discussed must be identified.
 - (4) The Wisconsin State Laboratory of Hygiene "Guidelines for Citizen Participation in WSLH Board Meetings" are published on its website: http:// www.slh.wisc.edu/index.shtml and printed copies are available on request. (See Appendix 5) [Section §6.12 approved 5/27/03 board meeting.]

Appendix 5

Guidelines for Citizen Participation at WSLH Board Meetings

The Wisconsin State Laboratory of Hygiene board provides opportunities for citizens to appear before the board to provide information to the board on items listed on the agenda. Such appearances shall be brief and concise. In order to accommodate this participation in the allotted time, the guidelines are as follows:

- A. Items to be brought before the board:
 - 1. The board Secretary and Chair will assign a specific time on the agenda to hear public comment when a request to speak has been received from a member of the public.
 - Individuals or organizations will be limited to a total of five (5) minutes to make a
 presentation to the board. Following the presentation board members may ask clarifying
 questions.
 - 3. An organization is limited to one (1) spokesperson on an issue.
 - 4. On complex issues, individuals wishing to appear before the board are encouraged to submit written materials to the board Secretary in advance of the meeting so the board may be better informed on the subject in question. Such information should be submitted to the board Secretary for distribution to all board members <u>no later than seven (7) working days</u> before the board meeting.
 - 5. No matters that are in current litigation may be brought before the board.
- B. The board encourages individuals to confine their remarks to broad general policy issues rather than the day-to-day operations of the Wisconsin State Laboratory of Hygiene.
- C. Citizens who have questions for board members should ask these questions prior to the board meeting, during any recess during the board proceedings, or after board adjournment.
- D. Written requests to appear before the WSLH Board of Directors should be submitted <u>no</u> <u>later than two (2) working days</u> prior to a scheduled board meeting.
- E. Submit written requests to: Secretary, Wisconsin State Laboratory of Hygiene Board of Directors C/O WSLH Director 465 Henry Mall Madison, WI 53706 Telephone: (608) 890-0288 Email: <u>nathaniel.javid@slh.wisc.edu</u>

BUSINESS ITEMS

Item 5. BOARD MEMBERS' MATTERS

Description of the Item:

Board Members' Matters will present board members with the opportunity to ask questions and/or discuss issues related to the Wisconsin State Laboratory of Hygiene.

Suggested Board Action:

Receive for information.

Staff Recommendations and Comments:

BUSINESS ITEMS

Item 6. INTRODUCTION TO DR. ERRIN RIDER & ROLE AS ASSOCIATE DIRECTOR FOR CLINICAL TESTING

Description of the Item:

Dr. James Schauer, Director, Wisconsin State Laboratory of Hygiene, will introduce our new Associate Director for Clinical Testing, Dr. Errin Rider. Dr. Rider's role at the laboratory will be explained to the Board along with an explanation of her position on the organizational chart.

Suggested Board Action:

Review and provide input.

Staff Recommendations and Comments:

BUSINESS ITEMS

Item 7. COVID-19 TESTING & RESPONSE

Description of the Item:

Dr. Allen Bateman, WSLH Communicable Disease Division, will provide the COVID-19 Testing & Response presentation to the Board.

Suggested Board Action:

Review and provide input.

Staff Recommendations and Comments:

BUSINESS ITEMS

Item 8. IMPACT OF COVID-19 PANDEMIC ON CYTOLOGY TESTING IN WISCONSIN

Description of the Item:

Dr. Kaitlin Sundling, WSLH Disease Prevention Division, will report on the impact of the COVID-19 pandemic on cytology testing in Wisconsin.

Suggested Board Action:

Review and provide input.

Staff Recommendations and Comments:

BUSINESS ITEMS

Item 9. WisCON & COVID-19 RESPONSE

Description of the Item:

Ernie Stracener, WSLH Occupational Health Division, will present on the COVID-19 response for Wisconsin's Health Consultation Services.

Suggested Board Action:

Review and provide input.

Staff Recommendations and Comments:

BUSINESS ITEMS

Item 10. PFAS & COVID-19 ENVIRONMENTAL TESTING

Description of the Item:

Presentation to the Board on PFAS and COVID-19 Environmental Testing by Dr. Kayley Janssen and Erin Mani in the WSLH Environmental Health Division.

Suggested Board Action:

Review and provide input.

Staff Recommendations and Comments:

BUSINESS ITEMS

Item 11. FINANCIAL REPORT

Description of the Item:

Kevin Karbowski, WSLH Chief Financial Officer, will provide an update the Financial Report to the Board.

Suggested Board Action: Review and provide input.

Staff Recommendations and Comments:

WISCONSIN STATE LABORATORY OF HYGIENE

FINANCIAL REPORT

FISCAL YEAR 2020

June 30, 2020

Contents

FINANCIAL STATEMENTS

Statement of income

Comparative income statement

Comparative balance sheet

Statement of cash flows

Notes to the financial statements

WISCONSIN STATE LABORATORY OF HYGIENE STATEMENT OF INCOME For the period July 1, 2019 through June 30, 2020

	Fiscal Year 2020 Actual	Fiscal Year 2020 Budget	Variance Over/(Under)	Variance % of Budget
SUPPORT AND REVENUE				
Laboratory Services Revenues (Note 2)				
Department of Health Services	\$8,067,485	\$6,809,816	\$1,257,669	18.5%
Newborn Screening	4,504,937	5,080,000	(575,063)	-11.3%
Driver Improvement Surcharge (OWI)	1,619,200	1,619,200	0	0.0%
Department of Natural Resources	722,022	900,000	(177,978)	-19.8%
University of Wisconsin Systems	806,302	842,328	(36,026)	-4.3%
Other Wisconsin State and Local Agencies	333,648	333,696	(48)	0.0%
Wisconsin State and Local Agencies	16,053,594	15,585,040	468,554	3.01%
Clinical	5,691,341	6,300,804	(609,463)	-9.7%
Proficiency Testing	3,264,688	3,171,054	93,634	3.0%
Occupational Health	1,694,103	1,894,000	(199,897)	-10.6%
National Atmospheric Deposition Program	1,721,243	1,777,308	(56,065)	-3.2%
Association of Public Health Laboratories	1,058,306	1,216,000	(157,694)	-13.0%
Federal Agencies	410,552	218,979	191,573	87.5%
Environmental Testing	1,354,943	1,346,781	8,162	0.6%
Other Nonagency	83,191	113,543	(30,352)	-26.7%
Nonagency	15,278,368	16,038,469	(760,101)	-4.7%
Sponsored Projects	6,806,283	6,674,290	131,993	2.0%
Earnings - Investment Income	174,078	260,000	(85,922)	-33.0%
Program Revenue	38,312,323	38,557,799	(245,476)	-0.6%
State General Program Revenue (GPR)	11,605,493	11,728,000	(122,507)	-1.0%
TOTAL SUPPORT AND REVENUE	49,917,816	50,285,799	(367,983)	-0.7%
EXPENSES				
Salaries	21,501,863	21,186,496	315,367	1.5%
Fringe Benefits	8,069,068	7,816,470	252,598	3.2%
Supplies & Services	16,492,949	15,473,230	1,019,719	6.6%
Transfer Overhead to UW	955,895	907,583	48,312	5.3%
Building Rent	3,160,227	3,156,804	3,423	0.1%
Depreciation	2,092,647	2,075,176	17,471	0.8%
Bad Debt Expense	2,799	32,000	(29,201)	-91.3%
Interest Expense	23,291	39,000	(15,709)	-40.3%
Loss From Disposal Of Assets	19,077	0	19,077	
	0	-		
TOTAL EXPENSES	52,317,816	50,686,759	1,631,057	3.2%
NET OPERATING INCOME (LOSS)	(\$2,400,000)	(\$400,960)	(\$1,999,040)	

WISCONSIN STATE LABORATORY OF HYGIENE COMPARATIVE INCOME STATEMENT For the 12 months ended June 30, 2020 and June 30, 2019

	Current Year Actual	Prior Year Actual	Variance Over/(Under)	Percentage Change
SUPPORT AND REVENUE				<u> </u>
Laboratory Services Revenues (Note 2)				
Department of Health Services	\$8,067,485	\$8,219,943	(\$152,458)	-1.9%
Newborn Screening	4,504,937	4,565,487	(60,550)	-1.3%
Driver Improvement Surcharge (OWI)	1,619,200	1,619,200	0	0.0%
Department of Natural Resources	722,022	697,934	24,088	3.5%
University of Wisconsin Systems	806,302	906,266	(99,964)	-11.0%
Other Wisconsin State and Local Agencies	333,648	335,493	(1,845)	-0.5%
Wisconsin State and Local Agencies	16,053,594	16,344,323	(290,729)	-1.78%
Clinical	5,691,341	6,537,841	(846,500)	-12.9%
Proficiency Testing	3,264,688	3,042,659	222,029	7.3%
Occupational Health	1,694,103	1,833,208	(139,105)	-7.6%
Association of Public Health Laboratories	1,058,306	1,078,487	(20,181)	-1.9%
National Atmospheric Deposition Program	1,721,243	1,930,170	(208,927)	-10.8%
Federal Agencies	410,552	212,597	197,955	93.1%
Environmental Testing	1,354,943	1,328,025	26,918	2.0%
Other Nonagency	83,191	210,620	(127,429)	-60.5%
Nonagency	15,278,368	16,173,607	(895,239)	-5.5%
Sponsored Projects	6,806,283	7,026,722	(220,439)	-3.1%
Earnings - Investment Income	174,078	272,440	(98,362)	-36.1%
Program Revenue	38,312,323	39,817,092	(1,504,769)	-3.8%
State General Program Revenue (GPR)	11,605,493	11,252,902	352,591	3.1%
TOTAL SUPPORT AND REVENUE	49,917,816	51,069,994	(1,152,178)	-2.3%
EXPENSES				
Salaries	21,501,863	20,016,392	1,485,471	7.4%
Fringe Benefits	8,069,068	7,446,361	622,707	8.4%
Supplies & Services	16,492,949	16,597,545	(104,596)	-0.6%
Transfer Overhead to UW	955,895	914,623	41,272	4.5%
Building Rent	3,160,227	3,085,347	74,880	2.4%
Depreciation	2,092,647	2,011,887	80,760	4.0%
Bad Debt Expense	2,799	16,479	(13,680)	-83.0%
Interest Expense	23,291	41,220	(17,929)	-43.5%
Loss From Disposal Of Assets	19,077	18,396	681	3.7%
TOTAL EXPENSES	52,317,816	50,148,250	2,169,566	4.3%
NET OPERATING INCOME (LOSS)	(\$2,400,000)	\$921,744	(\$3,321,744)	-360.4%

WISCONSIN STATE LABORATORY OF HYGIENE COMPARATIVE BALANCE SHEET As of June30, 2020 and June 30, 2019

ASSETS

CURRENT ASSETS \$9,056,018 \$11,822,355 Cash Cash-restricted-newborn screening surcharge \$9,056,018 \$11,822,355 Net accounts receivables (Note 3) 3,833,322 4,065,980 Other receivables 894,734 856,627 Inventories 41,433 55,3988 Prepaid expenses 94,484 81,942 Total current assets 14,908,192 18,445,464 EQUIPMENT AND BUILDING IMPROVEMENTS Equipment 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 6,878,228 Less accumulated depreciation (25,898,953) (24,494,960) Total Assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES Sataries and fringe benefits payable \$0 \$0 Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,27,027 1,148,966 Newb		June 30, 2020	June 30, 2019
Cash-restricted-newborn screening surcharge 997,595 1,564,612 Net accounts receivables 0000 3,833,922 4,065,960 Other receivables 034,734 856,627 Inventories 14,439 53,968 Prepaid expenses 94,484 81,942 Total current assets 14,908,192 18,445,464 EQUIPMENT AND BUILDING IMPROVEMENTS 6,878,228 6,878,228 Equipment 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 Current LiABILITIES 36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total net fixed assets 11,008,987 11,148,432 LIABILITIES Salaries and fringe benefits payable \$0 \$0 Accounts payable \$1,94 201,801 0 Deferred revenue 3,195 0 0 Compensated absences (Note 4) 726,983 650,591 Proficiency testing deferred revenue <td>CURRENT ASSETS</td> <td></td> <td></td>	CURRENT ASSETS		
Net accounts receivables (Note 3) 3,833,922 4,065,960 Other receivables 894,734 866,627 Inventories 94,484 81,942 Total current assets 14,493 53,988 Prepaid expenses 94,484 81,942 Total current assets 14,908,192 18,445,464 EQUIPMENT AND BUILDING IMPROVEMENTS 6,878,228 6,878,228 Equipment 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 Accounts payable 36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$0 \$0 \$0 Accounts payable \$0 \$0 \$0 Accounts payable \$0 \$0 \$0 Compensated absences (Note 4) 726,983 650,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 1,276,027 1,864,612	Cash		
Other receivables 894,734 856,627 Inventories 41,439 53,968 Prepaid expenses 94,484 81,942 Total current assets 14,908,192 18,445,464 EQUIPMENT AND BUILDING IMPROVEMENTS 6,876,228 6,876,228 Equipment 30,029,713 28,765,164 Building improvements 6,876,228 6,876,228 Gestard 36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total net fixed assets 11,008,987 11,148,432 CURRENT LIABILITIES Salaries and fringe benefits payable \$0 \$0 Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,148,4966 Newborn screening surcharge payable 987,555 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compens			
Inventories 41,439 53,968 Prepaid expenses 94,484 81,942 Total current assets 14,908,192 18,445,464 Equipment 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 Building improvements 36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total assets \$25,917,179 \$29,593,896 LIABILITIES Salaries and fringe benefits payable \$0 \$0 Accounts payable \$1,95 0 \$0 Accounts payable 3,195 0 \$0 Compensated absences (Note 4) 726,983 659,591 \$1,564,612 Proficiency testing deferred revenue 2,423,699 2,423,699 \$2,423,699 Newborn screening deferred revenue 2,424,999 2,423,699 \$1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391			
Prepaid expenses 94,484 81,942 Total current assets 14,908,192 18,445,464 EQUIPMENT AND BUILDING IMPROVEMENTS 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 6,878,228 Schoop,941 35,643,392 Less accumulated depreciation (26,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES Salaries and fringe benefits payable \$0 \$0 \$0 Accounts payable \$195 0 \$0 CURRENT LIABILITIES Salaries and fringe benefits payable \$0 \$0 Accourd expenses 78,194 201,801 0 Deferred revenue 3,195 0 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 2,423,699 2,423,699 Newborn screening deferred revenue 2,424,999 2,423,699 Compensated Absences (Note 4) 1,868,391 1,674,824 Total cu			
Total current assets 14,908,192 18,445,464 EQUIPMENT AND BUILDING IMPROVEMENTS 30,029,713 28,765,164 Equipment 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES AND EQUITY CURRENT LIABILITIES Salaries and fringe benefits payable 451,860 974,502 Accounts payable 3,195 0 \$0 Compensated absences (Note 4) 726,983 655,591 Proficiency testing deferred revenue 1,127,027 1,184,966 1,868,391 1,674,824 Newborn screening surcharge payable 5,799,853 7,009,171 LONG TERM DEBT 2 Compensated Absences (Note 4) 1,868,391 1,674,824 1,674,824 Total labilities 5,799,853 7,009,171 LONG TERM DEBT 2 2,253,381 2,060,980 <			
EQUIPMENT AND BUILDING IMPROVEMENTS Equipment 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES AND EQUITY Salaries and fringe benefits payable 451,860 974,502 Accounts payable 451,860 974,502 Accounts payable 451,860 974,502 Accounts payable 3,195 0 0 Compensated absences (Note 4) 726,983 655,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 1,643,944 2,060,980 Total labilities 7,668,244 8,683,995 EQUITY 2,253,381 2,060,980	Prepaid expenses	94,484	81,942
Equipment 30,029,713 28,765,164 Building improvements 6,878,228 6,878,228 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES \$25,917,179 \$29,593,896 Salaries and fringe benefits payable \$0 \$0 Accounts payable \$1,860 974,502 Accounts payable \$1,95 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue \$1,127,027 1,184,966 Newborn screening deferred revenue \$2,424,999 \$2,423,699 Newborn screening surcharge payable \$7,99,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 1,674,824 Total long term debt 1,2653,381 2,060,980 Total long term debt 1,2653,381 2,060,980 Total restricted retained earnings	Total current assets	14,908,192	18,445,464
Building improvements 6,878,228 6,878,228 6,878,228 6,878,228 6,878,228 6,878,228 36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES AND EQUITY \$0 \$0 Accounts payable \$0 \$0 Accounts payable \$1,860 974,502 Account expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,883 659,591 Proficiency testing deferred revenue 2,424,999 2,423,699 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total labilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 2,253,381 2,060,980 Operating contingency<	EQUIPMENT AND BUILDING IMPROVEMENTS		
36,907,941 35,643,392 Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES AND EQUITY CURRENT LIABILITIES \$0 \$0 Salaries and fringe benefits payable \$0 \$0 \$0 Accounts payable 451,860 974,502 \$26,933 659,591 Deferred revenue 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) Operating contingency 2,253,381 2,060,980 <t< td=""><td>Equipment</td><td>30,029,713</td><td>28,765,164</td></t<>	Equipment	30,029,713	28,765,164
Less accumulated depreciation (25,898,953) (24,494,960) Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES AND EQUITY \$0 \$0 Accounts payable \$0 \$0 \$0 Accounts payable \$1,148,432 \$0 \$0 Accounts payable \$0 \$0 \$0 Accounts payable \$1,94 201,801 \$0 Compensated absences (Note 4) 726,983 659,591 \$0 Proficiency testing deferred revenue 1,127,027 1,184,966 \$0 Newborn screening deferred revenue 2,424,999 2,423,699 \$0 Newborn screening surcharge payable \$7,99,853 7,009,171 \$20 LONG TERM DEBT \$1,868,391 1,674,824 \$1,674,824 Total long term debt 1,868,391 1,674,824 \$1,688,391 \$1,674,824 Total long term debt 1,868,391 2,060,980 \$2,060,980 \$2,253,381 2,060,980 \$2,253,381 2,060,980 </td <td>Building improvements</td> <td>6,878,228</td> <td>6,878,228</td>	Building improvements	6,878,228	6,878,228
Total net fixed assets 11,008,987 11,148,432 Total Assets \$25,917,179 \$29,593,896 LIABILITIES AND EQUITY Salaries and fringe benefits payable \$0 \$0 Accounts payable \$0 \$1,494 201,801 Deferred revenue 3,195 0 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,148,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 5,799,853 7,009,171 LONG TERM DEBT 0 1,674,824 Total labilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 2,253,381 2,060,980 Otal restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Operating Income (Loss) (2,400,000) 921,744	-	36,907,941	35,643,392
Total Assets \$25,917,179 \$29,593,896 LIABILITIES AND EQUITY CURRENT LIABILITIES \$0 \$0 Salaries and fringe benefits payable \$0 \$10 \$0 Accoud expenses 78,194 201,801 201,801 Deferred revenue 3,195 0 \$0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total Land Liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total lang term debt 1,868,391 1,674,824 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 0 2,253,381 2,060,980 Operating contingency 2,253,381 2,060,980 12,761,047 12,292,662 Contributed capital 5,634,516 <td< td=""><td>Less accumulated depreciation</td><td>(25,898,953)</td><td>(24,494,960)</td></td<>	Less accumulated depreciation	(25,898,953)	(24,494,960)
Liabilities \$0 \$0 CURRENT LIABILITIES \$0 \$0 Salaries and fringe benefits payable \$0 \$0 Accounts payable 451,860 974,502 Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 2,253,381 2,060,980 Total Liabilities 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Total restricted retained earnings (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662	Total net fixed assets	11,008,987	11,148,432
CURRENT LIABILITIES Salaries and fringe benefits payable \$0 \$0 Accounts payable 451,860 974,502 Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744	Total Assets	\$25,917,179	\$29,593,896
Salaries and fringe benefits payable \$0 \$0 Accounts payable 451,860 974,502 Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating lncome (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained	LIABILITIES AND EQUITY		
Accounts payable 451,860 974,502 Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 2,253,381 2,060,980 EQUITY Retained earnings-restricted (Note 5) 0 Operating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total unr	CURRENT LIABILITIES		
Accounts payable 451,860 974,502 Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 2,253,381 2,060,980 EQUITY Retained earnings-restricted (Note 5) 0 Operating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total unr	Salaries and fringe benefits payable	\$0	\$0
Accrued expenses 78,194 201,801 Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 2,253,381 2,060,980 EQUITY Retained earnings-restricted (Note 5) 0perating contingency 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 8 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902		451,860	974,502
Deferred revenue 3,195 0 Compensated absences (Note 4) 726,983 659,591 Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT 0 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 0perating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 12,761,047 12,292,662 Net Operating Income (Loss) (2,400,000) 921,744 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 18,248,944 20,909,902			
Proficiency testing deferred revenue 1,127,027 1,184,966 Newborn screening deferred revenue 2,424,999 2,423,699 Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT 1,868,391 1,674,824 Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 0perating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 12,761,047 12,292,662 Net Operating Income (Loss) (2,400,000) 921,744 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 18,248,944 20,909,902	Deferred revenue	3,195	0
Newborn screening deferred revenue Newborn screening surcharge payable 2,424,999 2,423,699 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT 2 2 2 Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Compensated absences (Note 4)	726,983	659,591
Newborn screening surcharge payable 987,595 1,564,612 Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 0perating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 12,761,047 12,292,662 Net Operating Income (Loss) (2,400,000) 921,744 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Proficiency testing deferred revenue	1,127,027	1,184,966
Total current liabilities 5,799,853 7,009,171 LONG TERM DEBT 1,868,391 1,674,824 Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Newborn screening deferred revenue	2,424,999	2,423,699
LONG TERM DEBT Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Newborn screening surcharge payable	987,595	1,564,612
Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 0 Operating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Total current liabilities	5,799,853	7,009,171
Compensated Absences (Note 4) 1,868,391 1,674,824 Total long term debt 1,868,391 1,674,824 Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 0 Operating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	LONG TERM DEBT		
Total Liabilities 7,668,244 8,683,995 EQUITY Retained earnings-restricted (Note 5) 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902		1,868,391	1,674,824
EQUITY Retained earnings-restricted (Note 5) Operating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Total long term debt	1,868,391	1,674,824
Retained earnings-restricted (Note 5) 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Total Liabilities	7,668,244	8,683,995
Operating contingency 2,253,381 2,060,980 Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	EQUITY		
Total restricted retained earnings 2,253,381 2,060,980 Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Retained earnings-restricted (Note 5)		
Net Operating Income (Loss) (2,400,000) 921,744 Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Operating contingency	2,253,381	2,060,980
Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Total restricted retained earnings	2,253,381	2,060,980
Retained earnings-unrestricted 12,761,047 12,292,662 Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902	Net Operating Income (Loss)	(2,400,000)	921,744
Contributed capital 5,634,516 5,634,516 Total unrestricted retained earnings 15,995,563 18,848,922 Total Equity 18,248,944 20,909,902			12,292,662
Total Equity 18,248,944 20,909,902	-		
	Total unrestricted retained earnings	15,995,563	18,848,922
Total Liabilities and Equity \$25,917,188 \$29,593,897	Total Equity	18,248,944	20,909,902
	Total Liabilities and Equity	\$25,917,188	\$29,593,897

WISCONSIN STATE LABORATORY OF HYGIENE STATEMENT OF CASH FLOWS For the 12 months ended June 30, 2020 and June 30, 2019

	Current Year	Prior Year
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	(\$2,400,000)	\$921,744
Adjustments to reconcile net income to net cash provided by operating		
activities:		
Depreciation	2,092,647	2,011,887
Changes in working capital components:		
Decrease/(Increase) in net accounts receivables	232,038	207,141
Decrease/(Increase) in other receivables	(38,107)	(213,729)
Decrease/(Increase) in inventories	12,529	(9,862)
Decrease/(Increase) in prepaid expenses	(12,542)	214,273
(Decrease)/Increase in salaries payable	0	(20,906)
(Decrease)/Increase in accounts payable	(522,642)	364,834
(Decrease)Increase in accrued expenses	(123,607)	48,637
(Decrease)Increase in deferred revenue	3,195	(17,740)
(Decrease)Increase in proficiency testing deferred revenue	(57,939)	131,033
(Decrease)/Increase in newborn screen deferred revenue	1,300	117,400
(Decrease)/Increase in newborn screening surcharge payable	(577,017)	(356,526)
Net cash provided (used) in operating activities	(1,390,145)	3,398,186
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of equipment and physical plant improvements	(1,953,209)	(3,025,906)
Net cash provided (used) in investing activities	(1,953,209)	(3,025,906)
CASH FLOWS FROM FINANCING ACTIVITIES		
Principal payment on Capital Lease	0	0
Net cash provided (used) in financing activities	0	0
Net increase (decrease) in cash	(3,343,354)	372,280
Cash:		
Beginning	13,386,967	13,014,687
Ending	\$10,043,613	\$13,386,967

WISCONSIN STATE LABORATORY OF HYGIENE NOTES TO THE FINANCIAL STATEMENTS For the period July 1, 2019 through June 30, 2020

NOTE 1 - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

Nature of Business:

The Wisconsin State Laboratory of Hygiene (WSLH) is a governmental institution which provides medical, industrial and environmental laboratory testing and related services to individuals, private and public agencies, including the Department of Natural Resources (DNR) and the Department of Health Services (DHS). Approximately 75% of the WSLH operating revenues are program revenues, including contracts, grants, and fee-for-service billing. The remainder are general purpose revenues (GPR), which are Wisconsin state general fund dollars.

Budgetary Data:

Fiscal Year 2019-2020 operating budget amounts were approved by the WSLH Board on June 18, 2019.

Basis of Presentation:

The financial statements have been prepared on a modified accrual basis following Generally Accepted Accounting Principles (GAAP).

Basis of Accounting:

- Revenues are recognized at the completion of the revenue generating processes. Fee-forservice revenues are generally recognized in the period services are completed.
- Revenues from GPR, OWI, Grants, and expense reimbursement contracts for salaries, fringe benefits, capital, and supplies are recognized as expended.
- Expenses are recognized and accrued when the liability is incurred.

Estimates and assumptions:

 The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from those estimates.

Assets:

- Cash is considered restricted if, by prior agreement with an outside entity, it must be segregated for future use by the outside entity or by WSLH at the outside entity's behest. As of June 30, 2020 available cash is restricted in an amount equal to the newborn screening surcharge payable to the Wisconsin Department of Health Services.
- Accounts receivable are reported at net realizable value. Net realizable value is equal to the gross amount of receivables less an estimated allowance for uncollectible amounts.
- Inventory is stated at cost (first in, first-out method).
- Equipment and building improvements are carried at cost. Expenditures for assets in excess of \$5,000 are capitalized. Depreciation is computed by the straight-line method.

Liabilities

 A liability for unearned revenue is recognized for prepaid receipts for WSLH-provided Proficiency Testing programs and for prepaid newborn screening tests.

NOTE 2 - LABORATORY SERVICES REVENUES

At the Board's request, Laboratory Service Revenues on the Income Statement have been divided into two groups, Agency and Non-Agency, as follows:

Agency:

Department of Health Services Newborn Screening Driver Improvement Surcharge (OWI) Department of Natural Resources University of Wisconsin Systems **Municipalities** Law Enforcement Agencies Department of Agriculture, Trade and Consumer Protection Office of Justice Assistance Wisconsin Emergency Management Non-Agency: UW Hospital Authority Medicare and Medicaid **Proficiency Testing Occupational Health** Federal Agencies All other revenue from individuals, businesses, clinics, and hospitals,

NOTE 3 - ACCOUNTS RECEIVABLE

Accounts receivable and allowance for uncollectible account balances as of June 30, 2020 and June 30, 2019 are as follows:

	<u>June 30, 2020</u>	<u>June 30, 2019</u>
Accounts Receivable Total	\$3,932,433	\$4,170,961
Allowance for bad debt	<u>(98,511)</u>	(105,000)
Net Receivables	\$3,833,922	\$4,065,961

NOTE 4 - COMPENSATED ABSENCES

- GASB Statement No. 16, "Accounting for Compensated Absences," establishes standards of accounting and reporting for compensated absences by state and local governmental entities for which employees will be paid such as vacation, sick leave, and sabbatical leave. Using the criteria in Statement 16, a liability for compensated absences that is attributable to services already rendered and that is not contingent on a specific event that is outside the control of the State and its employees has been accrued. The table below details the liability by benefit category:

				Legal	
	Total	Vacation	Pers Hol	Hol	Sabbatical
Current	\$726,983	\$552,775	\$63,669	\$3,610	\$106,929
Long					
Term	1,868,391				1,868,391
	\$2,595,374	\$552,775	\$63,669	\$3,610	\$1,975,320

NOTE 5 - RETAINED EARNINGS - RESTRICTED

The operating contingency is computed annually and reflects two months of salary and fringe benefit cost for positions funded from program revenues. The contingency fund is considered adequately funded if working capital is greater than the contingency fund restriction. As of June 30, 2020 working capital (current assets less current liabilities) was \$9,108,348 thereby meeting the target contingency reserve requirement of \$2,253,381.

BUSINESS ITEMS

Item 12. HUMAN RESOURCES REPORT

Description of the Item:

Cynda DeMontigny, WSLH Human Resources Director, will provide the HR update from the period of June 6 to September 6, 2020 to the Board.

<u>Suggested Board Action:</u> Receive for information.

Staff Recommendations and Comments:

BUSINESS ITEMS

Item 13. DIRECTOR'S REPORT

- a) Dr. James Schauer, Director, WSLH
- 1. Public Relations Report
- 2. Water Boil Notice Report

Report to the Wisconsin State Laboratory of Hygiene Board Water Systems Tests by the WSLH

June 1 – August 31 2020

<u>There were no water boil notices during</u> <u>this period.</u>

Report to the Wisconsin State Laboratory of Hygiene Board

Representative Public or Environmental Health Incidents of Educational Interest June 10 – September 8, 2020

Agent or Event	Description	Current
Name	·	Status
	OUTBREAKS and INCIDENTS	
COVID-19 virus	In early March, only the WSLH and the City of Milwaukee Health Dept. Lab were testing for COVID-19 virus in the state. Since then the WSLH Communicable Disease Division (CDD) has helped bring 80+ labs in the state online for testing and also added multiple different testing platforms. The WSLH continues to perform COVID-19 testing for specimens that fit public health laboratory criteria, which includes outbreak response. The WSLH is also very involved in the state's response at the State Emergency Operations Center on the testing workgroup (Communicable Disease Division) and in PPE decontamination training (WisCon). The WSLH is collaborating with the Wisconsin Veterinary Diagnostic Laboratory and University Health Services to stand up a COVID-19 virus testing lab on the UW-Madison campus to perform up to 6,000 tests weekly for UW students, faculty and staff. With funding from the WI Department of Health Services, the WSLH is also performing population-based surveillance testing. The WSLH Communicable Disease Division is performing antibody testing for the Past Antibody COVID-19 Community Survey (PACCS) . This study is being led by the Survey of the Health of Wisconsin (SHOW) in the UW School of Medicine and Public Health and "will determine the prevalence of COVID-19 antibodies throughout the state."	Ongoing
		NameOUTBREAKS and INCIDENTSCOVID-19 virusIn early March, only the WSLH and the City of Milwaukee Health Dept. Lab were testing for COVID-19 virus in the state. Since then the WSLH communicable Disease Division (CDD) has helped bring 80+ labs in the state online for testing and also added multiple different testing platforms. The WSLH continues to perform COVID-19 testing for specimens that fit public health laboratory criteria, which includes outbreak response.The WSLH continues to perform COVID-19 testing for specimens that fit public health laboratory criteria, which includes outbreak response.The WSLH is also very involved in the state's response at the State Emergency Operations Center on the testing workgroup (Communicable Disease Division) and in PPE decontamination training (WisCon).The WSLH is collaborating with the Wisconsin Veterinary Diagnostic Laboratory and University Health Services to stand up a COVID-19 virus testing lab on the UW-Madison campus to perform up to 6,000 tests weekly for UW students, faculty and staff.With funding from the WI Department of Health Services, the WSLH is also performing population-based surveillance testing.The WSLH Communicable Disease Division is performing antibody testing for the Past Antibody COVID-19 Community Survey (PACCS). This study is being led by the Survey of the Health of Wisconsin (SHOW) in the UW School of Medicine and Public Health and "will determine the prevalence of COVID-19

		WSLH Environmental Microbiology has developed methods and are performing testing for a statewide wastewater surveillance study. The surveillance study will provide for trend analysis and potential early detection of SARS- CoV-2, the virus that causes COVID-19, in communities across the state by monitoring viral RNA in influent streams at wastewater treatment facilities (WWTFs). This project is also a collaboration with the WI Department of Natural Resources and researchers at UW-Milwaukee. The WSLH is also testing wastewater from 2 locations on the UW-Madison campus as part of campus COVID-19 response. WisCon also received funding via DHS to enable consultants to work with businesses to develop COVID-19 occupational health and safety prevention plans .	
	F	RECENT EVENTS and FINDINGS	
February 2020 – present	COVID-19 media interviews	CDD leadership (Pete Shult, Allen Bateman, and Alana Sterkel) have done 40+ media interviews for state and national media about COVID-19 testing. WSLH COVID-19 wastewater surveillance project scientists (Martin Shafer, Kayley Janssen and Dagmara Antkiewicz) have done about half dozen more. Media interviews continue for both the clinical testing and wastewater scientists.	Ongoing
March – September, 2020	Communicable Disease Division	Since the early days of the COVID-19 Pandemic the Communicable Disease Division has been sharing information and keeping WI clinical laboratorians and local public health officials up to date with the most current COVID-19 testing information via webinars. Archived webinars (12 so far) and slides are posted to our COVID-19 web page under the "Resources" section - http://www.slh.wisc.edu/clinical/diseases/covid- 19/. Webinars will continue as long as needed.	Ongoing

April - September 2020	WDPH Clinician Webinars WDPH Local Health Officer/ Department webinars WI Health Care Association (skilled nursing, long-term care, assisted living facilities)	Allen Bateman and Alana Sterkel, Assistant Directors in CDD, presented COVID-19 laboratory updates at the weekly statewide WDPH clinician webinars attended by 400-800 people. Al presented in April and August and Alana in September. Alana has also presented multiple times on DPH Local Health Officer and Health Department webinars and has presented twice to WI Health Care Association members.	Ongoing
June – Aug, 2020	Society of Forensic Toxicologists (SOFT) Annual Conference	The SOFT annual meeting is cancelled and a virtual event is planned in its place. Forensic Toxicology Section Chemist Supervisor Bill Johnson is Chair of the Scientific Program for the virtual event. Bill coordinated all of the abstracts for the program, reviewing approximately 40 submitted abstracts, and scheduled each one for the program.	Complete
June – August 2020	National Safety Council – Alcohol, Drugs and Impairment Division (ADID)	Forensic Toxicology Director Amy Miles is a member of NSC-ADID and works with this group to survey forensic toxicology labs across the country every 3 years. The survey is then collated into recommendations for laboratories performing DUID casework. The recommendations provide scope of testing and cutoff concentrations for drugs of abuse. A publication in a peer-reviewed journal is forthcoming.	Complete
June 26, 2020	APHL Gold Standard Award for Public Health Laboratory Excellence	WSLH Chemical Emergency Response Coordinator Noel Stanton received the Association of Public Health Laboratories (APHL) Gold Standard Award for Public Health Laboratory Excellence at an online ceremony on June 26 th . This award is given to an APHL member that makes or has made significant contributions to the technical advancement of public health laboratory science and/or practice.	Complete

June 29, 2020	Drug Impaired Driving Webinar	Forensic Toxicology Director Amy Miles presented in a webinar in conjunction with "Tall Cop Says Stop" to provide drug trend and human performance effects to law enforcement.	Complete
July 2020	WSLH Brown Bag	Allen Bateman, Assistant Director in CDD, presented "SARS-CoV-2/COVID-19 Laboratory update".	Complete
July 2020	Association of Molecular Pathology (AMP) Education Committee	Allen Bateman, Assistant Director in CDD, was elected to be on the AMP Training and Education Committee.	Complete
July 2020	Constellation Research's Business Transformation 150	WSLH Office of Information Systems Director Allen Benson has been named to Constellation Research's Business Transformation 150 – an annual list of global executives leading business transformation efforts in their organization. Nominations for the list come from peers, industry influencers, technology vendors and analysts.	Complete
July 2020	Traffic Injury Research Foundation (TIRF)	Forensic Toxicology Director Amy Miles was asked by TIRF to assist in the assessment of the Nevada forensic toxicology laboratory system. The state has 3 separate forensic toxicology labs, each functioning independently. This project included assessing each lab and discussing the current state with partners (Law enforcement, judges, Cannabis compliance, etc.). The final report will be presented to the state of Nevada legislators and NHTSA for review and implementation. Wisconsin is considered a model program for other forensic toxicology laboratories and much of the recommendations mirror the current practices at the WSLH.	Complete
July 2020	Russian translation of Paris System for Reporting Urinary Cytopathology	WSLH Medical Director and Disease Prevention Director Dr. Dan Kurtycz is one of three editors of the <i>Paris System for Reporting Urinary</i> <i>Cytopathology</i> . The book was written by the Paris System Working Group - comprised of cytopathologists, surgical pathologists and urologists – who developed a standardized reporting system for the cytologic interpretation of urine samples to aid in the detection of	Complete

		bladder cancer. The book has been translated into Japanese and the Russian translation was just published. The Chinese translation is expected soon.	
July 2020	Association of Public Health Labs (APHL) Opioids Biosurveillance Task Force	Forensic Toxicology Director Amy Miles is on the APHL Opioids Biosurveillance Task Force (OBTF). Over the last year, the OBTF has completed a model biosurveillance strategy which was released in July 2020 <u>https://www.aphl.org/aboutAPHL/publications/</u> <u>Documents/EH-2020-Opioid-Biosurveillance-</u> <u>Strategy.pdf</u> The WSLH Forensic Toxicology lab and its work on opioids biosurveillance in the state and nationally is <u>featured</u> in the spring issue of the Association of Public Health Laboratories (APHL) <u>Lab Matters</u> magazine.	Complete
July 2020	Laboratory Genetics and Genomics Fellows	The WSLH welcomed two new Laboratory Genetics and Genomics Fellows in July. The two- year competitive fellowship program is accredited by the Accreditation Council for Graduate Medical Education (ACMGE). XQ Shao has served as a Research Specialist in the WSLH Molecular Genetics Department since 2017. He received his PhD in Genetics from the University of Wisconsin-Madison, his MS in Biomedical Sciences from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) and his BS in Biotechnology from Nanjing University, in Nanjing, China. Gregory Fischer has served as an Associate Human Molecular Geneticist and Scientific Director of DNA Banking for Prevention Genetics in Marshfield, WI. He received his PhD in Genetics from the University of Wisconsin- Madison and his BS in Biochemistry/Molecular Biology from the University of Wisconsin-Eau Claire.	Complete
August 2020	UW Cytotechnology Program – Virtual	Like many UW classes this semester, this year's Cytotechnology Certificate Program students are learning virtually but with an added twist – their	Ongoing



		Jess Konopatski	
August 2020	CDC contract award	The WSLH Chemical Emergency Response Program was granted a five year contract to administer the international Lead and Multi- Element Program (LAMP) with CDC. Funding of \$50K/year supports the WSLH role in this lab evaluation program for toxic elements in whole blood.	Complete
August 2020	DRE Ambassador Award	 WSLH Forensic Toxicology Director Amy Miles was awarded the Drug Recognition Expert (DRE) Ambassador award at the International Chiefs of Police - Drugs, Alcohol, and Impaired Driving online conference. The DRE Ambassador is awarded to an individual who, while never having been certified as a DRE, has made significant contribution to the Drug Evaluation and Classification (DEC) Program. DRE's are law enforcement officers who undergo extensive training to recognize the varying signs of impairment that different drugs can cause in drivers. 	Complete
August 2020	SARS-CoV-2 journal article	 WSLH Communicable Disease Division had an article about pooling specimens for SARS-CoV-2 testing accepted: Allen Bateman, Shanna Mueller, Kyley Guenther, Pete Shult. Assessing the Dilution Effect of Specimen Pooling on the Sensitivity of SARS-CoV-2 PCR Tests. Journal of Medical Virology. 2020. In press. 	Complete

August 13, 2020	Drinking Water and Groundwater Study Group Meeting	 WSLH Environmental Microbiologist Kayley Janssen presented on "Molecular Methods for Safer Waters and Public Health in Wisconsin" at the August Drinking Water and Groundwater Study Group Meeting. Her presentation was recorded as part of the meeting https://dnr.wisconsin.gov/sites/default/files/topi c/DrinkingWater/StudyGroup/DNRPresentation2 0200803.pdf starting at ~ 3:20. 	Complete
August 24, 2020	DNR PFAS accreditation	The WSLH received PFAS accreditation from the WI Department of Natural Resources for Drinking Water Method EPA 537.1. We are awaiting word on further PFAS accreditations from DNR. We expect to hear about non-potable water accreditation sometime this fall.	Complete
August 24, 2020	Oklahoma Justice and Recovery Conference	Forensic Toxicology Director Amy Miles recorded 2 presentations for the state of Oklahoma. The webinars will be provided to various partners/stakeholders in Oklahoma for continuing education. The topic of the webinars were general forensic toxicology information and current drug trends.	Complete
August 25, 2020	APHL Cannabis Testing Webinar	Forensic Toxicology Director Amy Miles coordinated and moderated a webinar for APHL. The topic of the webinar was Cannabis testing in PHLs and Forensic Laboratories. The intent of the webinar is to compare/contrast the testing between the two types of labs.	Complete
August 31, 2020	Acumatica ERP Project Update	The formal Acumatica ERP (Enterprise Resource Planning) project has kicked off and is in full gear in phase one. The team is having weekly update meetings and the design phase is underway. We are very excited to have the new Financial Manager for Accounts Receivable and Credit Management, Tip Vandall, join the implementation team. Her experience will be a great asset to the project.	In Process